RKI-1447 is a potent inhibitor of Rho-associated coiled-coil containing protein kinases (ROCK), particularly ROCK2. It is widely used in research to study cellular processes regulated by the Rho/ROCK signaling pathway, such as cell migration, cytoskeletal organization, and cell contraction. Due to its ability to block ROCK-mediated phosphorylation, RKI-1447 has shown promise in cancer research, where it inhibits the invasion and migration of various tumor cells, including breast, liver, and melanoma cancer cells. It has also been investigated for its potential to induce apoptosis in cancer cells without affecting normal cell viability. In addition to oncology, RKI-1447 is explored in studies related to fibrosis, where ROCK signaling contributes to tissue scarring, and in ophthalmology for its potential to modulate intraocular pressure by affecting trabecular meshwork cell tone. Its application remains primarily in preclinical research, serving as a tool compound for understanding disease mechanisms and evaluating therapeutic strategies.